Ritu Salani, MD

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

A comprehensive overview of recent clinical trial data on PARP inhibitors in the first-line maintenance setting in ovarian cancer presented at ASCO 2023.

An expert panel highlights current unmet needs in the maintenance setting for ovarian cancer.

Experts on ovarian cancer discuss germline and somatic testing practices and provide clinical insights on factors that influence treatment decisions.

A panel of expert gynecologic oncologists introduce themselves and review frontline maintenance treatment options in ovarian cancer.

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.

Ritu Salani, MD, MBA, discusses the importance of histological subtyping and molecular profiling in developing treatment strategies and improving outcomes for patients with endometrial cancer.

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

Ritu Salani, MD, provides insight into how to approach selection of chemotherapy in ovarian cancer.

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Ritu Salani, MD, discusses selecting patients with ovarian cancer for primary debulking surgery versus neoadjuvant chemotherapy.

Ritu Salani, MD, discusses considerations for neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.